tiprankstipranks
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
Company AnnouncementsArcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
15d ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
PremiumRatings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
16d ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
PremiumRatings
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
22d ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
PremiumCompany Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
27d ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
PremiumRatings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
27d ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
PremiumCompany AnnouncementsArcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
28d ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
Premium
The Fly
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
28d ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
PremiumMarket News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
2M ago
WGS
ARCT
Arcturus Therapeutics initiated with a Buy at B. Riley
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at B. Riley
3M ago
ARCT
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
3M ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
PremiumCompany Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
3M ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
PremiumCompany AnnouncementsArcturus Therapeutics Balances Pipeline Progress With Cash Strain
3M ago
ARCT
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
Premium
The Fly
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
3M ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
Premium
Ratings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
3M ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
PremiumRatings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
3M ago
ARCT
Arcturus Therapeutics price target raised to $8 from $7 at Citi
PremiumThe Fly
Arcturus Therapeutics price target raised to $8 from $7 at Citi
3M ago
ARCT
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
PremiumThe Fly
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
3M ago
ARCT
Options Volatility and Implied Earnings Moves Today, March 03, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 03, 2026
3M ago
AZO
BBY
ARCT Earnings this Week: How Will it Perform?
PremiumPre-EarningsARCT Earnings this Week: How Will it Perform?
3M ago
ARCT
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
Premium
Company Announcements
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
4M ago
ARCT
Arcturus Therapeutics initiated with a Buy at Roth Capital
Premium
The Fly
Arcturus Therapeutics initiated with a Buy at Roth Capital
4M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >